Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial was terminated before completing — can you find out why it was stopped, and what that means for whether this approach is considered safe or effective for my specific condition?
2. 2Since this was a Phase 1 study using gene-modified donor T cells after a stem cell transplant, what safety concerns or side effects were being watched for, and were any serious problems reported before it was terminated?
3. 3Because the trial was measuring both adverse events and engraftment, does the available data suggest whether the gene-modified T cells were actually taking hold in patients, or is that still unclear?
4. 4Given that this trial is no longer enrolling, are there other active studies using gene-modified T cells for my condition — such as a primary immune deficiency or bone marrow failure syndrome — that might be worth looking into instead?
5. 5Before considering any experimental T cell approach, would it make sense for me to try standard treatment options first, and how would that affect my eligibility for similar future trials?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.